Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.58 |
| ▸ | GAA | P10253 | 4/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 6/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.56 |
| ▸ | CRHBP | P24387 | 1/20 | 0.53 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10771702 | 0.85 | MAPT (0.57) | ALDH1A1GAAKMT2AMAPTLMNA | |
| SCHEMBL4279296 | 0.85 | MAPT (0.57) | ALDH1A1GAAKMT2AMAPTLMNA | |
| SCHEMBL22838052 | 0.84 | MAPT (0.53) | ALDH1A1GAAKMT2AMAPTLMNA | |
| SCHEMBL4053767 | 0.84 | MAPT (0.56) | ALDH1A1GAAKMT2AMAPTLMNA | |
| SCHEMBL1345244 | 0.83 | KMT2A (0.56) | GAAKMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL427393 | 0.83 | KMT2A (0.56) | GAAKMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL1345434 | 0.83 | KMT2A (0.56) | GAAKMT2AMAPTLMNAL3MBTL1 | |
| SCHEMBL11795322 | 0.83 | MAPT (0.52) | ALDH1A1GAAKMT2AMAPTLMNA | |
| SCHEMBL1857441 | 0.83 | MAPT (0.54) | ALDH1A1GAAKMT2AMAPTLMNA | |
| SCHEMBL5611041 | 0.83 | MAPT (0.54) | ALDH1A1GAAKMT2AMAPTLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 40 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024020350-A1 | TEAD INHIBITORS AND METHODS OF USE | SPOROS BIODISCOVERY, INC. (US) | 2024-01-25 | — | — | WO | disclosed |
| WO-2021027721-A1 | IMMUNOMODULATOR | 成都先导药物开发股份有限公司 | 2021-02-18 | — | — | WO | disclosed |
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-10-26 | — | — | US | disclosed |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-08-31 | — | — | US | disclosed |
| US-9630970-B2 | TYK2 inhibitors and uses thereof | NIMBUS LAKSHMI, INC. (US) | 2017-04-25 | — | — | US | disclosed |
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-10-13 | — | — | US | disclosed |
| WO-2016138352-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2016-09-01 | — | — | WO | disclosed |
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2016-09-01 | — | — | US | disclosed |
| WO-2008125342-A2 | NOVEL VANILLOID RECEPTOR LIGANDS AND THE USE THEREOF FOR THE PRODUCTION OF PHARMACEUTICALS | Grünenthal GmbH (DE) | 2008-10-23 | — | — | WO | disclosed |
| US-4720506-A | Immunomodulating agent | NIPPON SHINYAKU COMPANY, LIMITED (JP) | 1988-01-19 | — | — | US | disclosed |
| EP-0094599-B1 | USE OF AMINOPHENYLACETIC ACID DERIVATIVES FOR THE MANUFACTURE OF AN IMMUNOMODULATING MEDICAL PREPARATION | MITSUBISHI KASEI CORPORATION (JP) | 1987-04-01 | — | — | EP | disclosed |
| EP-0094599-A1 | Use of aminophenylacetic acid derivatives for the manufacture of an immunomodulating medical preparation | MITSUBISHI KASEI CORPORATION (JP) | 1983-11-23 | — | — | EP | disclosed |
| US-4337264-A | ANALGESICS, ANTIINFLAMMATORY AGENTS AND FUNGICIDES | CIBA-GEIGY CORPORATION (US) | 1982-06-29 | — | — | US | disclosed |
| US-4316850-A | ANTINFLAMMATORY AGENTS | CIBA-GEIGY CORPORATION (US) | 1982-02-23 | — | — | US | disclosed |
| US-4264619-A | Tertiary aminoacids | CIBA-GEIGY CORPORATION (US) | 1981-04-28 | — | — | US | disclosed |
| US-4163788-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1979-08-07 | — | — | US | disclosed |
| US-4126691-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1978-11-21 | — | — | US | disclosed |
| US-3997669-A | ANTIINFLAMMATORY | CIBA-GEIGY CORPORATION (US) | 1976-12-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160297826-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885GAA 1899/4885KMT2A 206/4885 |
| US-20160251376-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885GAA 1899/4885KMT2A 206/4885 |
| US-20170305933-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885GAA 1899/4885KMT2A 206/4885 |
| US-20170247373-A1 | TYK2 INHIBITORS AND USES THEREOF | TYK2, JAK2, JAK1 | ALDH1A1 4827/4885GAA 1899/4885KMT2A 206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.